Navigation Links
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Date:4/25/2008

levels of HCV RNA (<15 IU/mL), or RVR. Following 4 weeks of treatment with R7128 500mg BID with Pegasys plus Copegus, patients achieved a mean 3.82 log10 IU/mL decrease in HCV RNA and 30% (6 of 20) had RVR. Following 4 weeks of treatment with placebo with Pegasys plus Copegus, patients achieved a mean 2.95 log10 IU/mL decrease in HCV RNA and 10% (1 of 10) had RVR. The baseline HCV RNA levels for all patients in the study were greater than 6.3 log10 IU/mL and were similar across all study groups.

Safety Summary

Safety and tolerability for the 4-week treatment period were similar for R7128 with Pegasys plus Copegus compared to placebo with Pegasys plus Copegus. There were no serious adverse events reported during the 4-week treatment period, and most of the adverse events reported were of mild to moderate intensity. The most common adverse events, reported in 15% or greater of patients in any treatment group during the 4-week treatment period, were headache, injection site reaction, myalgia, fatigue, chills, rash, nausea, diarrhea, arthralgia, pyrexia, dizziness, dyspepsia and pruritis. The frequency and severity of these adverse events, as well as any general body system observations, were generally similar to clinical experience with the standard of care for HCV, pegylated interferon plus ribavirin.

Grade 3/4 neutropenia was observed in 30% of the placebo patients and in 10% to 15% of the R7128 patients in each active dosing cohort. Grade 3 changes in hemoglobin were observed in 10% of the placebo patients and in 15% of the R7128 patients. There were no clinically significant changes in other hepatic, renal, or other safety laboratory parameters, vital signs, or electrocardiograms.

Overall, there was no clinical evidence of any major organ toxicities related to R7128. One patient in the active treatment group discontinued the study during the 4 week treatment period due to lower-gastrointestinal adverse events. At the time of study discon
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
7. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
8. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
9. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... -- MedicOne Medical Response, a leading provider emergency ... by Inc. Magazine as one of the fastest ... Photo - http://photos.prnewswire.com/prnh/20140914/145997 ... companies with the largest revenue growth between 2010 ... two ambulance companies to make the list, achieved ...
(Date:9/15/2014)...  Catalist-listed QT Vascular Ltd. ("QT Vascular" or together ... of minimally invasive medical devices for the treatment of ... has enrolled the first European patients in the ENDURE ... have already been enrolled in this study with Dr. ... Auckland, New Zealand . ...
(Date:9/15/2014)... , Sept. 15, 2014  Over 200 patients, ... roof Saturday to learn, interact and participate in ... City,s first Lupus Trials Fair launched by the ... S.L.E. Lupus Foundation .  Attendees interacted directly ... -- sharing experiences, ideas and needs and learning ...
Breaking Medicine Technology:MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3
... ROCHESTER, N.Y., Sept. 8 VirtualScopics, Inc. (Nasdaq: ... for clinical trials, announced today that Ms. Molly Henderson, ... presenting a corporate overview at the Rodman & Renshaw ... City. Ms. Henderson,s presentation will be on Tuesday, September ...
... N.J., Sept. 8 Today every major pharmaceutical industry ... the future of pharma.  In an unprecedented move, they,re ... the big names in pharma.  All in one place. ... at the Pharma CI Conference & Exhibition at the ...
Cached Medicine Technology:VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference 2Pharmaceutical Industry Insiders, VIPs All Coming Together for Future of Pharma Market, Pharmaceutical Competitive Intelligence 2
(Date:9/15/2014)... (PRWEB) September 15, 2014 Imaging can ... for stroke who might benefit from aggressive intervention, according ... journal Radiology. , The study looked at people ... major blood vessels supplying blood to the head due ... the primary cause of up to 20 percent of ...
(Date:9/15/2014)... OAK BROOK, Ill. Imaging can be a cost-effective ... might benefit from aggressive intervention, according to a new ... . , The study looked at people with ... blood vessels supplying blood to the head due to ... primary cause of up to 20 percent of ischemic ...
(Date:9/15/2014)... San Diego, CA (PRWEB) September 15, 2014 ... has announced its next two-day DISC Certification Workshop ... and HR professionals will meet locally to take part ... be provided with effective tools and activities that can ... certification is designed to teach trainers to educate employees ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 The new ... Monday, Sept. 15 near Raintree Dr. and Loop 101, ... Jim Lane and dignitaries from the healthcare community on ... contains seven operating rooms, four gastro-intestinal procedure rooms, and ... making it the largest surgery center in the state ...
(Date:9/15/2014)... 15, 2014 The Best Hospitals ... Report consists of seven hospitals using OnBase as their ... and Cleveland Clinic were ranked at the top of ... The rankings cover nearly 5,000 medical centers across the ... hospitals that scored highest in at least six of ...
Breaking Medicine News(10 mins):Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 2Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 3Health News:Imaging identifies asymptomatic people at risk for stroke 2Health News:Imaging identifies asymptomatic people at risk for stroke 3Health News:DISCcert Announces Two-day DISC Certification Workshop Oct 16 and 17 2Health News:DISCcert Announces Two-day DISC Certification Workshop Oct 16 and 17 3Health News:New North Valley Surgery Center Is Arizona’s Largest Outpatient Facility 2Health News:New North Valley Surgery Center Is Arizona’s Largest Outpatient Facility 3Health News:New North Valley Surgery Center Is Arizona’s Largest Outpatient Facility 4Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2
... ... 25 years experience to the workplace resources company , ... Chicago, IL (PRWEB) April 28, 2010 -- ... behavioral healthcare, work/life services, organizational development and wellness services, welcomes Rick Kronberg ...
... to liver failure in some, British researchers say , ... for a mild high is popular in East Africa ... seen among certain immigrant groups in Great Britain and ... severe liver damage and even death, British researchers report. ...
... effective in less than half of cases, study finds , ... identified vitamin E as a treatment that can provide relief ... the most common chronic liver disease. , "This clearly shows ... nonalcoholic steatohepatitis who don,t have active diabetes," said study author ...
... ... retailer of health and fitness products for people who are serious about ... 2010. ,Established in 2000 in Newcastle-upon-Tyne, originally as a mail order company, ... event by launching a new, even more user-friendly website packed with exciting ...
... with a brain arteriovenous malformation (AVM), an abnormal tangle ... of vessel rupture and bleeding that can cause stroke ... preventative interventions, such as endovascular procedures, surgical resection, or ... on the assumption that unruptured AVMs pose similar risk ...
... Md., April 28, 2010 In a major crackdown, ... operating in the country to close within the past ... against Counterfeit & Substandard Medicines (IMC), the shops were ... primary sources of substandard and counterfeit medicines in the ...
Cached Medicine News:Health News:Rick Kronberg Joins Perspectives Ltd As Director of Clinical Services 2Health News:Chewing Khat Linked to Severe Liver Damage 2Health News:Vitamin E Helps Treat Common Liver Disease 2Health News:Vitamin E Helps Treat Common Liver Disease 3Health News:Slimming Solutions Celebrates 10 Years in Business with the Launch of a New Weight Loss Website 2Health News:Do unruptured brain vessel malformations need preventative surgery? 2Health News:Do unruptured brain vessel malformations need preventative surgery? 3Health News:Cambodia takes action in fight against substandard and counterfeit medicines 2Health News:Cambodia takes action in fight against substandard and counterfeit medicines 3
... The Driver Stent design, utilizing ... the limitations of stainless steel ... possible thinner struts, for unparalleled ... The Driver Coronary Stent Systemwith ...
... Guiding Catheter provides support to enhance ... under adverse conditions. It gives you ... to your destination in cardiac interventions. ... variety of clinical situations and the ...
... Catheters are intended for use ... applications. They provide a pathway ... as balloon dilatation catheters, guide ... may be introduced. These devices ...
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
Medicine Products: